



**FOR IMMEDIATE RELEASE**

Contact: Gina Jung  
ACIST Medical Systems  
952-995-9306  
[gina.jung@acistmedical.com](mailto:gina.jung@acistmedical.com)

**Minneapolis, MN, September 29, 2008** -- ACIST Medical Systems, Inc. (a Bracco Group company), a world leader in advanced contrast injection systems for cardiovascular angiography and diagnostic imaging, announced today the signing of a distribution agreement for the StatSensor Creatinine Meter with Nova Biomedical. The agreement calls for the ACIST and Nova teams to co-exclusively market and distribute the StatSensor Creatinine Meter into the medical fields of Radiology and Cardiology, initially within North America. Within this new distribution structure, both ACIST and Nova will focus on providing its customer's with seamless continuity for the StatSensor solution from point of care deployment in imaging modalities where iodine and gadolinium derived intravenous contrast agents are administered, to platform management, and its connectivity into the clinical laboratory. ACIST will continue to support customers who have previously purchased the StatSensor Creatinine Meter under the E-Z-Chem brand name from E-Z-EM, Inc. prior to the acquisition of certain assets by ACIST Medical Systems.

The StatSensor Creatinine device quickly measures a patient's blood creatinine level and calculates their eGFR (estimated glomerular filtration rate) prior to contrast agent administration via a finger prick. Blood creatinine levels and eGFR are key clinical factors allowing the clinician to assess patient renal function and eligibility for IV contrast administration thereby minimizing the potential for CIN (Contrast Induced Nephropathy) which can include such serious conditions as renal impairment from iodine based contrast to NSF (Nephrogenic Systemic Fibrosis) from gadolinium based contrast.

"We are fortunate and pleased to enhance our partnership with Nova Biomedical team to better serve our customer base with the innovative StatSensor Creatinine Meter." said Fulvio Renoldi-Bracco, CEO of ACIST Medical Systems, Inc. "With ACIST Medical Systems and its affiliation with the Bracco Group, a world leader in contrast media for both x-ray and magnetic resonance imaging procedures, inclusion of the Nova StatSensor within our contrast and contrast delivery

product portfolio, we can bring clinicians and patients a range of solutions capable of helping to provide an improved standard of care."

According to Frank Manganaro, CEO of Nova Biomedical, "StatSenosr Creatinine Meter is ideally suited for both the Radiology and Cardiology channels. Nova is excited about the opportunity to partner with ACIST because of their strength in both of these markets."

### **About ACIST**

ACIST Medical Systems, a Bracco Group company, is a pioneer and market leader of Advanced Contrast Imaging System Technology in the fields of cardiology and radiology with a global clinical presence in over 40 countries. ACIST Medical Systems directly employs over 220 people worldwide, with the majority located at its newly expanded corporate headquarters in Eden Prairie, Minnesota. Device manufacturing, research and development, technical and customer service, and all other corporate functions are performed from these offices in support of the global marketplace. Two other regional offices in Europe and Asia further coordinate local sales and system activities.

ACIST Medical Systems is dedicated to helping clinicians provide the best patient care possible, by delivering innovative solutions that aid in obtaining quality images with greater ease and control during every procedure, in every case. ACIST Medical Systems is relentlessly "in pursuit of the perfect image" through continuous research and development of new products and technologies – supporting today's needs and anticipating those of tomorrow.

### **Bracco Group Overview**

Founded in 1927, the Bracco Group is today a worldwide integrated Healthcare Group, one of the world leading companies in the imaging agent business, with annual revenue of more than 900 million Euro — around 50% of which is from foreign sales. Bracco SpA, holding company of the Bracco Group, also markets ethical and over the counter pharmaceutical products and healthcare services in Italy, as well as Advanced Medical Technology systems on a world wide basis through the ACIST Medical Systems, based in Minneapolis. Bracco is present in approximately 80 countries both directly and through joint-ventures or affiliates, and currently employs more than 2,300 people worldwide, over 300 of which are dedicated to Research & Development, Medical and Regulatory Affairs.